

## Product Specification Sheet

**Product Name:** ACY-1215 (Rocilinostat)

**Catalog Number:** C2121

**Technical information:**

Chemical Formula:  $C_{24}H_{27}N_5O_3$

CAS #: 1316214-52-4

Molecular Weight: 433.5

Purity: > 98%


Appearance: White solid

Solubility: Soluble in DMSO up to 100 mM

Chemical Name: 2-(diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide

Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.231 mL of DMSO for each mg of ACY-1215 (Rocilinostat)
  - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:** ACY-1215 (Rocilinostat) is an orally-available, hydroxamic acid-based, selective inhibitor of HDAC6 and HDAC8 with IC<sub>50</sub> values of 5 nM and 100 nM, respectively. ACY-1215 is 12-, 10-, and 11-fold less active against HDAC1, HDAC2, and HDAC3, respectively, and has minimal activity (IC<sub>50</sub> > 1 μM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1 and Sirtuin2. [1]

To demonstrate ACY-1215 selectivity for HDAC6, MM.1S cells were cultured with increasing doses of ACY-1215 for 6 hours. Dose-dependent increased acetylated α-tubulin was observed at low doses (0.62 μM) with no effect on histone acetylation.

ACY-1215 has been shown to work synergistically with bortezomib in multiple myeloma models.

**Reference:** 1. Santo et al., Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. *Blood* 2012, 119, 2579-2589. Pubmed ID: 22262760

For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

*For research use only, not for clinical or diagnostic use.*